X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

VRDN

Closed

Viridian Therapeutics Inc

14.47
+0.49 (+3.51%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 13.98
Day's Range: 13.84 - 14.91
Send
When Written:
 
25.03
Viridian Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing novel therapies for patients with autoimmune and inflammatory diseases. The company's lead product candidate, VRDN-001, is a potential treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases.

VRDN-001 is a fusion protein that targets the B-cell activating factor (BAFF), a protein that plays a critical role in the activation and survival of B-cells, which are involved in the pathogenesis of autoimmune diseases. The drug is designed to selectively inhibit the BAFF pathway and reduce the number of autoreactive B-cells, which can lead to a reduction in disease activity and symptoms.

Viridian Therapeutics was founded in 2017 and is headquartered in Cambridge, Massachusetts. The company is led by a team of experienced biotech executives and scientists with a track record of developing successful therapies for autoimmune and inflammatory diseases. Viridian Therapeutics is funded by leading biotech investors, including ARCH Venture Partners, Fidelity Management & Research Company, and Flagship Pioneering.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X